Previous reports proposed that the IgM anti-dsDNA antibody is protective for lupus nephritis. In this cross-sectional study, we aimed to compare clinical features of systemic lupus erythematosus (SLE) patients positive for IgG anti-dsDNA alone with those presenting both IgG and IgM anti-dsDNA. Anti-dsDNA antibodies, urinary examination and complement levels were assessed in the day of appointment. IgG and IgM anti-dsDNA antibodies were detected by indirect immunofluorescence. Fifty-eight SLE patients (93.1% female, 81% European-derived, mean age 42.8±14.7 years, mean duration of disease 10.9±8 years) positive for IgG anti-dsDNA entered the study. Of those, 15 were also positive for the IgM anti-dsDNA isotype. The group with both isotypes showed significant less frequency of active nephritis (sediment changes and proteinuria) when compared to patients with IgG anti-dsDNA alone (6.7% versus 34.9%, p=0.046). These data suggest a nephroprotective role for IgM anti-dsDNA and a distinct biologic behavior for this isotype in SLE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866685 | PMC |
| http://dx.doi.org/10.2174/1874312901307010101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating clinical data and genetic susceptibility to elucidate the relationship between systemic lupus erythematosus and human cytomegalovirus infection.
Virol J
November 2024
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology & Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China.
Background: Viral infections are known to induce the occurrence and pathogenesis of systemic lupus erythematosus (SLE). Previous studies have indicated a possible relationship between SLE and human cytomegalovirus (HCMV) infection and have attributed HCMV to be associated with various autoantibodies; however, these studies were constrained by variations in sample size and potential selection bias. Therefore, in the present study, we aimed to elucidate the relationship between HCMV and autoantibodies in patients with SLE by integrating clinical data and genetic susceptibility.
View Article and Find Full Text PDFSevere Antiphospholipid Syndrome and Diffuse Glomerulonephritis After Adalimumab Treatment in a Patient With Ulcerative Colitis.
Case Rep Rheumatol
November 2024
Division of Rheumatology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico, USA.
Tumor necrosis factor alpha inhibitors (TNFi) are biological drugs used worldwide to treat various autoimmune disorders. Paradoxically, TNF- antagonists can also induce autoimmune diseases being systemic vasculitis, systemic lupus erythematosus, and psoriasis, the most common. We present a 22-year-old woman with ulcerative colitis (UC) who was started on adalimumab 40 mg subcutaneously every 2 weeks.
View Article and Find Full Text PDFIs Idiopathic Granulomatous Mastitis a Subgroup of Systemic Lupus Erythematosus? A Preliminary Study.
J Clin Med
October 2024
Department of Radiology, Medical Faculty, Van Yüzüncü Yıl University, Van 65090, Turkey.
Article Synopsis
- The study evaluated the effectiveness of the systemic lupus erythematosus risk probability index (SLERPI) in determining whether patients with idiopathic granulomatous mastitis (IGM) might have systemic lupus erythematosus (SLE).
- A total of 62 IGM patients and 55 healthy controls were analyzed, focusing on demographic, clinical, and laboratory data, including various autoantibodies.
- Results showed that 19.4% of IGM patients tested positive for SLERPI, indicating a notable association with arthritis and certain autoantibodies, suggesting SLERPI can help identify potential SLE cases within the IGM population.
Comparison of Clinical and Laboratory Characteristics in Lupus Nephritis vs. Non-Lupus Nephritis Patients-A Comprehensive Retrospective Analysis Based on 921 Patients.
J Clin Med
July 2024
Jagiellonian University Medical College, Department of Rheumatology and Immunology, Jakubowskiego 2, 30-688 Kraków, Poland.
Article Synopsis
- Lupus nephritis (LN) is a kidney inflammation linked to systemic lupus erythematosus (SLE), and the study investigated the clinical and laboratory differences between LN and non-LN SLE patients at a university hospital in Kraków, Poland.
- Out of 921 SLE patients analyzed, 331 had LN, which presented at a younger age (29 vs. 37 years) and a higher male proportion compared to non-LN patients, who also had a higher occurrence of certain antibodies like anti-cardiolipin IgM.
- LN patients showed more severe symptoms, required more immunosuppressive treatment, and had specific risk factors for experiencing multiple LN flares, underscoring the need for
The reduced frequency of CD39CD73 B cell subsets in SLE patients is correlated with disease activity.
Int Immunopharmacol
October 2024
Department of Clinical Laboratory Medicine, Nanjing Drum Tower Hospital, Clinical College, Jiangsu University, Nanjing, Jiangsu 210008, China; Department of Clinical Laboratory Medicine, Nanjing Drum Tower Hospital, Clinical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210008, China; Department of Clinical Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China. Electronic address:
Background: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by immune mechanisms dysregulation, leading to the production of diverse autoantibodies. However, the immune pathways underlying B-cell function and phenotypic abnormalities related to SLE pathogenesis remain incompletely understood.
Objective: To explore new markers of SLE activity and potential targets for SLE immunotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!